

### Appendix 3 (as supplied by the authors): Studies excluded from meta-analysis

Study	Reason for exclusion
Abbatecola et al 2006(1)	Not comparing intervention of interest*
Adetuyibi et al 1977(2)	Duration of intervention less than 24 weeks
Adlung et al 1974(3)	Not a randomized clinical trial
Ahuja et al 1973(4)	Not a randomized clinical trial
Akanuma et al 1988(5)	Not comparing interventions of interest
Almer 1984(6)	Not a randomized clinical trial
Alvarsson et al 2010(7–9)	Not comparing intervention of interest*
Aman et al 1977(10)	Not a randomized clinical trial
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Type 2 Diabetes Patients with Cardiovascular History (APPROACH) trial 2010(11–13)	Not comparing intervention of interest*
Baba et al 1983(14)	Not comparing intervention of interest
Balabolkin et al 1983(15)	Not a randomized clinical trial
Balabolkin et al 1988(16)	Not a randomized clinical trial
Banerji et al 1995(17)	Not including participants with type 2 diabetes
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial(18)	Not comparing interventions of interest.
Bellomo et al 2011(19)	Duration of intervention less than 24 weeks
Belovalova et al 1990(20)	Not a randomized clinical trial
Ben et al 1988(21)	Not a randomized clinical trial
Berber et al 1982(22)	Duration of intervention less than 24 weeks
Bernas et al 1992(23)	Not a randomized clinical trial
Berry et al 1981(24)	Not a randomized clinical trial
Birkeland et al 1994(25)	Not comparing intervention of interest*
Birkeland et al 2002(26–28)	Not comparing intervention of interest*
Blumenbach et al 1976(29)	Not a randomized clinical trial
Bruns et al 1990(30)	Duration of intervention less than 24 weeks
Calvagno et al 1983(31)	Not a randomized clinical trial
Cefalu et al 1998(32)	Duration of intervention less than 24 weeks
Ceriello et al 2005(33)	Not a randomized clinical trial
Chan et al 1982(34)	Not comparing intervention of interest
Chandra et al 2008(35)	Not a randomized clinical trial. Authors asked and replied.
Charbonnel et al 2005(36,37)	Not comparing intervention of interest*
Chen et al 1987(38)	Not a randomized clinical trial
Coniff et al 1983(39)	Not comparing intervention of interest*
Cortinovis et al 1998(40)	Not a randomized clinical trial
Dalzell et al 1986(41)	Not comparing intervention of interest*
Deng 2003(42)	Not comparing intervention of interest*
Derosa et al 2003(43)	Not comparing intervention of interest*
Derosa et al 2010(44)	Not comparing intervention of interest

Diehl et al 1985(45)	Not comparing intervention of interest*
Dills et al 1996(46)	Not comparing intervention of interest
Dowey et al 1979(47)	Not a randomized clinical trial
Drouin et al 2000(48)	Not comparing intervention of interest
Drouin et al 2004(49)	Not comparing intervention of interest
Duprey et al 1971(50)	Not a randomized clinical trial
Ebeling et al 2001(51)	Not comparing intervention of interest*
Engelhardt 1965(52)	Includes also participants with normal glucose tolerance
Esposito et al 2004(53)	Not comparing intervention of interest*
Feinböck et al 2003(54)	Not comparing intervention of interest*
Ferner et al 1991(55)	Not a randomized clinical trial
Fineberg et al 1980(56)	Not comparing intervention of interest*
Foley et al 2009(57,58)	Not comparing intervention of interest*
Forst et al 2003(59)	Not comparing intervention of interest*
Forst et al 2005(60,61)	Not comparing intervention of interest*
Forst et al 2011(62)	Not a randomized clinical trial
Fuchs 1973(63)	Duration of intervention less than 24 weeks in publication. Not comparing intervention of interest*
Garber et al 2002(64,65)	Duration of intervention less than 24 weeks
Garber 2003(66)	Duration of intervention less than 24 weeks
Gargiolo et al 2001(67)	Not a randomized clinical trial
Giles et al 2008(68)	Not comparing intervention of interest
Giles et al 2010(69)	Not comparing intervention of interest
Goldberg et al 1996(70)	Duration of intervention less than 24 weeks
Groop et al 1989(71)	Not comparing intervention of interest
Gudat et al 1998(72)	Not a randomized clinical trial
Gurling 1970(73)	Not a randomized clinical trial
Happ et al 1974(74)	Duration of intervention less than 24 weeks
Hanefeld 2007(75–77)	Not comparing intervention of interest*
Harrower 1985(78)	Not comparing intervention of interest*
Haupt et al 1974(79)	Not a randomized clinical trial
Hoffmann 1990(80,81)	Not comparing intervention of interest*
Hoffmann et al 1994(82)	Not comparing intervention of interest*
Hollander et al 1992(83)	Not comparing intervention of interest*
Hollander et al 2001(84)	Duration of intervention less than 24 weeks
Howes 2000(85)	Not a randomized clinical trial
Hristov et al 2002(86)	Not a randomized clinical trial
Hussain 2007(87)	Not comparing intervention of interest
Inukai et al 2005(88)	Not comparing intervention of interest
Irsigler et al 1979(89)	Duration of intervention less than 24 weeks
Ishizuka et al 1994(90)	Not a randomized clinical trial
Jackson et al 1969(91)	Not a randomized clinical trial
Jain et al 2006(92)	Not comparing intervention of interest*

Jerums et al 1987(93)	Not comparing intervention of interest
Jibran et al 2006(94)	Not comparing intervention of interest*
Johnston et al 1970(95)	Duration of intervention less than 24 weeks
Johnston et al 1997(96)	Not comparing intervention of interest*
Josephkutty et al 1990(97)	Duration of intervention less than 24 weeks
Joshi et al 2002(98)	Duration of intervention less than 24 weeks
Kakhnovskii et al 1993(99)	Not a randomized clinical trial
Kaku et al 2011(100–103)	Not comparing intervention of interest*
Kanda 1998(104)	Not comparing intervention of interest*
Kanoun et al 1996(105)	Not a randomized clinical trial
Kovacevic et al 1997(106)	Not comparing intervention of interest*
Langenfeld et al 2005(107)	Not comparing intervention of interest
Lecomte et al 1977(108)	Duration of intervention less than 24 weeks
Levy et al 1995(109)	Duration of intervention less than 24 weeks
Li et al 2009(110)	Not comparing intervention of interest
Lim et al 1970(111)	Duration of intervention less than 24 weeks
Lindbjerg et al 1976(112)	Duration of intervention less than 24 weeks
Liu et al 1985(113)	Duration of intervention less than 24 weeks
Lomuscio et al 1994(114)	Not a randomized clinical trial
Madsbad et al 2001(115)	Not comparing intervention of interest*
Mafauzy 2002(116)	Duration of intervention less than 24 weeks
Marbury et al 1999(117)	Not comparing intervention of interest*
Mazzone et al 2006(118)	Not comparing intervention of interest
Memisogullari et al 2009(119)	Not comparing intervention of interest*
Meneilly 2011(120)	Duration of intervention less than 24 weeks
Mogensen et al 1976(121)	Not comparing intervention of interest
Nakamura et al 2000(122)	Duration of intervention less than 24 weeks
Nakamura et al 2004(123)	Not comparing intervention of interest*
Nakamura et al 2006(124)	Not comparing intervention of interest*
Nathan et al 1988(125)	Not comparing intervention of interest*
Nikkilä et al 1982(126)	Not comparing intervention of interest
Nissen et al 2008(127)	Not comparing intervention of interest
Noury et al 1991(128)	Duration of intervention less than 24 weeks
Omrani et al 2005(129)	Assume not a randomized clinical trial
Osei et al 2003(130)	Not including participants with type 2 diabetes
Papa et al 2006(131)	Duration of intervention less than 24 weeks
Pagano et al 1995(132–134)	Not comparing intervention of interest*
Perez et al 2006(135)	Not comparing intervention of interest
Perriello et al 2007(136,137)	Not comparing intervention of interest*
Quatraro et al 1990(138)	Not comparing intervention of interest
Rao et al 2010(139)	Not comparing intervention of interest
Repaglinide studies(140–142)	Not comparing intervention of interest*
Rosenstock et al 1993(143)	Not comparing intervention of interest
Rosenthal et al 2002(144–146)	Not comparing intervention of interest*
Rosiglitazone Evaluated for Cardiovascular	Not comparing intervention of interest

Outcomes and Regulation of Glycaemia in Diabetes (RECORD) trial(147)	
Rupprecht et al 1993(148)	Not a randomized clinical trial
Saadatnia et al 2009(149)	Not a randomized clinical trial
Salman et al 2001(150)	Not comparing intervention of interest*
Sami et al 1996(151)	Not comparing intervention of interest
Sasahara et al 1999(152)	Not a randomized clinical trial
Schernthaner et al 2004(153)	Not comparing intervention of interest
Seck et al 2010(154)	Not comparing intervention of interest
Segal et al 1997(155)	Not comparing intervention of interest*
Shihara et al 2011(156,157)	Not comparing intervention of interest*
Shinoda et al 2009(158)	We assume not a randomized clinical trial. Attempt made to contact authors.
Speiser et al 1989(159)	Duration of intervention less than 24 weeks
Spengler et al 1992(160–164)	Not comparing intervention of interest*
Sung et al 1999(165)	Not comparing intervention of interest*
Sutton et al 2002(166,167)	Not comparing intervention of interest*
Tan et al 2004(168)	Not comparing intervention of interest*
Tan et al 2004a(169)	Not comparing intervention of interest*
Tan et al 2005(170)	Not comparing intervention of interest*
Teramoto et al 2007(171)	Not comparing intervention of interest*
The Liraglutide Effect and Action in Diabetes-3 (LEAD-3)(172–177)	Not comparing intervention of interest*
Tolman et al 2009(178)	Not comparing intervention of interest
Tovi et al 1998(179)	Not comparing intervention of interest
Toyota et al 1997(180)	Duration of intervention less than 24 weeks
Tsumara 1995(181)	Not comparing intervention of interest
Umpierrez et al 1997(182)	Not exclusively include patients with type 2 diabetes
University Group Diabetes Program(183–185)	Not comparing intervention of interest*
United Kingdom Diabetes Study 1998(186–190)	Not comparing intervention of interest*
Van de Laar et al 2004(191)	Not comparing intervention of interest*
Vray et al 1995(192)	Duration of intervention less than 24 weeks
Wang et al 1994(193)	Duration of intervention less than 24 weeks
Watanabe et al 2005(194)	Not comparing intervention of interest*
Wolffenbuttel et al 1989(195)	Not comparing intervention of interest*
Wolffenbuttel et al 1999(196)	Not comparing intervention of interest*
Wu et al 2010(197)	Duration of intervention less than 24 weeks
Yang et al 2009(198)	Not including participants with type 2 diabetes
Zhang et al 2005(199)	Not comparing intervention of interest*
Zhou 1999(200)	Duration of intervention less than 24 weeks

\*Included in the main Cochrane review [Hemmingsen B, Schroll JB, Lund SS, et al. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. *Cochrane Database of Sys Rev* 2013;(4):CD009008.]

## References

- (1) Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. *Neurology* 2006; 67(2):235-240.
- (2) Adetuyibi A, Ogundipe O. A comparative trial of glipizide, glibenclamide and chlorpropamide in the management of maturity-onset diabetes mellitus in nigerians. *Current Therapeutic Research Clinical and Experimental* 1977; 21(4):485.
- (3) Adlung J, Koch CD. Influence of tolbutamide on serum glucose level, specific activity of glucose and glucose oxidation in severe diabetes. *International Journal of Clinical Pharmacology, Therapy and Toxicology* 1974; 10(2):128-135.
- (4) Ahuja MM, Gupta SP, Sehgel VK. Efficacy of glibenclamide in maturity-onset diabetics as maintenance therapy. *Hormone and Metabolic Research* 1973; 5(3):160-163.
- (5) Akanuma Y, Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, Aoki S. Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas. *Diabetes Research and Clinical Practice* 1988; 5(2):81-90.
- (6) Almer LO. Effect of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes. *Thrombosis Research* 1984; 35(1):19-25.
- (7) Alvarsson M, Berntorp K, Fernqvist-Forbes E, Lager I, Steen L, Orn T et al. Effects of insulin versus sulphonylurea on beta-cell secretion in recently diagnosed type 2 diabetes patients: A 6-year follow-up study. *Review of Diabetic Studies* 2010; 7(3):231-238.
- (8) Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. *Diabetes Care* 2003; 26(8):2231-2237.
- (9) Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist-Forbes E, Steen L et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. *Diabetes, Obesity & Metabolism* 2008; 10(5):421-429.
- (10) Aman M, Jawad F, Sultana S, Waiz uH, Nanji R. Clinical trial with glipizide in uncomplicated maturity onset diabetes mellitus. *JPMA - Journal of the Pakistan Medical Association* 1977; 27(3):293-295.
- (11) GlaxoSmithKline. Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes. <http://clinicaltrials.gov/ct2/show/NCT00116831?term=nct00116831&rank=1> [ 2005
- (12) Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial. *Circulation* 2010; 121(10):1176-1187.

- (13) Ratner RE, Christopher PC, Gerstein HC, Nesto RW, Serruys PW, van Es GAe. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. *American Heart Journal* 2008; 156(6):1074-1079.
- (14) Baba S, Nakagawa S, Takebe K, Goto Y, Maezawa H, Takeda R et al. Double-Blind Randomized Control Study with Gliclazide. *Rinsho Hyoka (Clinical Evaluation)* 1983; 11(1):51-94.
- (15) Balabolkin MI, Morozova TP, Zhizhina SA, Novikova NV, Nepsha VD. [The effect of diamicon on various blood coagulation indices in patients with type II diabetes mellitus]. *Klinicheskaiia Meditsina* 1983; 61(4):66-68.
- (16) Balabolkin MI, Nedosugova LV. Effect of long-term therapy with sulfanylurea preparations on the relation of insulin secretion and the insulin-binding capacity of its receptors. *Terapevticheskii Arkhiv* 1988; 60(12):91-96.
- (17) Banerji MA, Chaiken RL, Lebovitz HE. Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. *Diabetes* 1995; 44(4):466-470.
- (18) BARI 2DSG. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *The New England Journal of Medicine* 2009; 360(24):2503-2515.
- (19) Bellomo DA, Stefanelli G, Laviola L, Giorgino R, Giorgino F. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. *Diabetic Medicine* 2011; 28(5):560-566.
- (20) Belovalova IM, Gamburtseva TD, Kniazeva AP, Matveeva LS, Starosel'tseva LK. The nature of the pancreatic hormone secretion and of the metabolic indices during the acute and chronic administration of peroral hypoglycemic preparations. *Problemy Endokrinologii* 1990; 36(1):14-20.
- (21) Ben Khelifa F, Sellami S, Abid M, Fitouhi B, Jerbi A, Jedidi S et al. Comparison of the hypoglycemic effect of 2 presentations--of glibenclamide. *La Tunisie Medicale* 1988; 66(12):887-893.
- (22) Berber MJ, Tomkin GH. The effects of gliclazide in diabetes: A comparison with tolbutamide. *Irish Journal of Medical Science* 1982; 151(2):46-49.
- (23) Bernas M, Czech A, Taton J. Relative effectiveness of tolbutamide, chlorpropamide and gliclazide. *Polski Tygodnik Lekarski* 1992; 47(1-2):35-39.
- (24) Berry EM, Bar-On H. Comparison of sulphonylurea and insulin treatment on lipid levels in maturity-onset diabetic men and women. *Israel Journal of Medical Sciences* 1981; 17(5):384-387.
- (25) Birkeland KI, Furueth K, Melander A, Mowinckel P, Vaaler S. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. *Diabetes Care* 1994; 17(1):45-49.

- (26) Birkeland KI, Hanssen KF, Urdal P, Berg K, Vaaler S. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. *Journal of Internal Medicine* 1994; 236(3):305-313.
- (27) Birkeland KI, Kilhovd B, Thorsby P, Torjesen PA, Ganss R, Vaaler S et al. Heterogeneity of non-insulin-dependent diabetes expressed as variability in insulin sensitivity, beta-cell function and cardiovascular risk profile. *Diabetic Medicine* 2002; 20:37-45.
- (28) Birkeland KI, Rishaug U, Hanssen KF, Vaaler S. NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. *Diabetologia* 1996; 39(12):1629-1633.
- (29) Blumenbach L, Kiesselbach N, Lehnert J. Further results of a multi-centre clinical trial with the oral antidiabetic drug glisoxepide. *Arzneimittel-Forschung* 1976; 26(5):931-943.
- (30) Bruns W, Jutzi E, Staritz B, Willkommen G, Willkommen G. Treatment of type II diabetics (non-insulin-dependent) for sulphonylurea secondary failure - combined therapy, using glibenclamid and insulin. *Zeitschrift für klinische Medizin* 1990; 45(11):983-986.
- (31) Calvagno M, Acacia E, Kremer P, Marowsky C, Maccione E, Taddey N et al. Clinical and biomedical study of a sulphonylurea hypoglycemic agent with action at vascular level. *Semana Médica* 1983; 162(20):799-808.
- (32) Cefalu WT, Bell-Farrow A, Wang ZQ, McBride D, Dalgleish D, Terry JG. Effect of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in NIDDM. *Drug Development Research* 1998; 44(1):1-7.
- (33) Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. *Diabetes Care* 2005; 28(2):266-272.
- (34) Chan TK, Chan V, Teng CS, Yeung RTT. Effects of gliclazide and glibenclamide on platelet function, fibrinolysis and metabolic control in diabetic patients with retinopathy. *Semaine des Hopitaux* 1982; 58(19):1197-1200.
- (35) Chandra ST, Priya G, Khurana ML, Jyotsna VP, Sreenivas V, Dwivedi S et al. Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. *Diabetes Technology & Therapeutics* 2008; 10(5):363-368.
- (36) Charbonnel B, Roden M, Urquhart R, Mariz S, Johns D, Mihm M et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. *Diabetologia* 2005; 48(3):553-560.
- (37) Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P, QUARTET S. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. *Diabetic Medicine* 2005; 22(4):399-405.

- (38) Chen H. Pharmacokinetic and clinical study on glibenclamide. *Zhonghua yi xue za zhi* 1987; 67(10):533-535.
- (39) Coniff RF, Shapiro JA, Seaton TB, Bray GAB. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. *The American Journal of Medicine* 1995; 98(5):443-451.
- (40) Cortinovis A, Crippa A, Sciacca V, Caravaggio V, Crippa M. Modificazioni emoreologiche, metaboliche ed emocogulative in diabetici in trattamento con sulfaniluree. *Minerva Medica* 1998; 79(5):391-398.
- (41) Dalzell GW, Hadden DR, Atkinson AB, Kennedy L, Weaver JA. A randomized trial of tolbutamide and metformin for persistent severe hypoglycaemia in non insulin dependent diabetes mellitus (NIDDM). *Irish Endocrine Society* 1986; 155(9):341-342.
- (42) Deng QW. Clinical observation on Xiayaosan modified for treatment of type 2 diabetes mellitus. *Hubei Journal of Traditional Chinese Medicine* 2003; 25(12):31-32.
- (43) Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factor. *Clinical Therapeutics* 2003; 25(2):472-484.
- (44) Derosa G, Maffioli P, Salvadeo SAT, Ferrari I, Ragonesi PD, Querci F et al. Exenatide versus glibenclamide in patients with diabetes. *Diabetes Technology and Therapeutics* 2010; 12(3):233-240.
- (45) Diehl AK, Sugarek NJ, Bauer RL. Medication compliance in non-insulin-dependent diabetes: a randomized comparison of chlorpropamide and insulin. *Diabetes Care* 1985; 8(3):219-223.
- (46) Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. *Hormone and Metabolic Research* 1996; 28(9):426-429.
- (47) Dowe KE, Grant AP, Hayes JR. Glipizide evaluation after a one year trial in maturity onset diabetics. *Ulster Medical Journal* 1979; 48(1):65-68.
- (48) Drouin P. Diamicon MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study. *Journal of Diabetes & its Complications* 2000; 14(4):185-191.
- (49) Drouin P, Standl E, Diamicon MR. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. *Diabetes, Obesity & Metabolism* 2004; 6(6):414-421.
- (50) Duprey J, Lubetzki J. [Insulin secretion in maturity-onset diabetes mellitus. Effects of the prolonged administration of glybutamide]. *La Presse Medicale* 1971; 79(54):2469-2471.



- (51) Ebeling P, Teppo A, Koistinen HA, Koivisto VA. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. *Metabolism* 2001; 50(3):283-287.
- (52) Engelhardt HT, Vecchio TJ. The long-term effect of tolbutamide on glucose tolerance in adult, asymptomatic, latent diabetics. *Metabolism* 1965; 14:885-890.
- (53) Esposito K, Giugliano D, Nappo F, Marfella RfCP. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. *Circulation* 2004; 110(2):214-219.
- (54) Feinböck C, Luger A, Klingler A, Egger T, Bielez GK, Winkler F et al. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. *Diabetes, Nutrition & Metabolism* 2003; 16(4):214-221.
- (55) Ferner RE, Antsiferov ML, Kelman AW, Alberti KGMM, Rawlins MD. The relationships between dose and concentration of tolbutamide and insulin and glucose responses in patients with non-insulin-dependent diabetes. *European Journal of Clinical Pharmacology* 1991; 40(2):163-168.
- (56) Fineberg SE, Schneider SH. Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations. *Diabetologia* 1980; 18(1):49-54.
- (57) Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.[Erratum appears in *Horm Metab Res.* 2009 Dec;41(12):909]. *Hormone & Metabolic Research* 2009; 41(12):905-909.
- (58) ClinicalTrials.gov. Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naïve Patients With Type 2 Diabetes.  
<http://clinicaltrials.gov/ct2/show/NCT00102388?term=nct00102388&rank=1> [ 2011
- (59) Forst T, Eriksson JW, Strotmann HJ, Bai S, Brunelle R, Gulliya KS et al. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes. *Experimental and Clinical Endocrinology & Diabetes* 2003; 111(2):97-103.
- (60) Forst T, Hohberg C, Fuellert SD, Lübben G, Konrad T, Löbig M et al. Pharmacological PPAR $\gamma$  stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. *Horm Metab Res* 2005; 37(8):521-527.
- (61) Forst T, Lübben G, Hohberg C, Kann P, Sachara C, Gottschall V et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. *Microcirculation* 2005; 12(7):543-550.

- (62) Forst T, Weber M, Pfützner A, Löbig M, Hohberg C, Fuchs W. C-Peptide and Intima Media Thickness in Type 2 Diabetes Mellitus Treated With Pioglitazone. *Diabetes Stoffwechsel Und Herz* 2011; 20(2).
- (63) Fuchs K. Glipizide versus tolbutamide in maturity-onset diabetes, an open comparative study. *Diabetologia* 1973; 9(Suppl):351-355.
- (64) Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D, Metformin Initial Therapy S. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. *Diabetes, Obesity & Metabolism* 2002; 4(3):201-208.
- (65) Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. *Clinical Therapeutics* 2002; 24(9):1401-1413.
- (66) Garber AJ, Donovan DS J, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism* 2003; 88(8):3598-3604.
- (67) Gargiulo P, Caccese D, Pignatelli P, Brufani C, De Vito F, Marino Re. Metformin decreases platelet superoxide anion production in diabetic patients. *Diabetes/Metabolism Research and Reviews* 2001; 18(2):156-159.
- (68) Giles TD, Miller AB, Elkayam U, Bhattacharya M, Perez A. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. *Journal of Cardiac Failure* 2008; 14(6):445-452.
- (69) Giles TD, Elkayam U, Bhattacharya M, Perez A, Miller AB. Comparison of Pioglitazone vs Glyburide in Early Heart Failure: Insights From a Randomized Controlled Study of Patients With Type 2 Diabetes and Mild Cardiac Disease. *Congestive Heart Failure* 2010; 16(3):111-117.
- (70) Goldberg RB, Holvey SM, Schneider J, Bansal S, Blonde L, Boden G et al. A Dose-Response Study of Glimepiride in Patients With Niddm Who Have Previously Received Sulfonylurea Agents. *Diabetes Care* 1996; 19(8):849-856.
- (71) Groop L, Widén E, Franssila-Kallunki A, Ekstrand A, Saloranta C, Schalin C et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1989; 32(8):599-605.
- (72) Gudat U, Bungert S, Kemmer F, Heinemann L. The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus. *Diabetic Medicine: a journal of the British Diabetic Association* 1998; 15(3):194-198.
- (73) Gurling KJ. A comparison of glibenclamide with chlorpropamide in newly diagnosed maturity-onset diabetes. *Postgraduate Medical Journal* 1970; -(Suppl):66-69.
- (74) Happ J, Beyer J, Nest E, Fröhlich A, Althoff PH, Schöffling K. Blood sugar, serum insulin, nonesterified fatty acids and somatotropin in daily profile in adult diabetics

- under monotherapy with various sulfonylureas. *Arzneimittel-Forschung* 1974; 24(8):1228-1234.
- (75) Charbonnel B, Lonnqvist F, Jones NP. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after one year of treatment in type 2 diabetic patients. *Diabetes* 1999; 48(Suppl 1).
- (76) GlaxoSmithKline. A Multicentre, Double-Blind, Parallel Group Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone vs. Glibenclamide Therapy, When Administered to Patients with Type 2 Diabetes Mellitus. GSK Homepage 2011; Study No.: 49653/020.
- (77) Hanefeld M, Patwardhan R, Jones NP. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. *Nutrition, Metabolism & Cardiovascular Diseases* 2007; 17:13-23.
- (78) Harrower AD. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. *Current Medical Research and Opinion* 1985; 9(10):676-680.
- (79) Haupt E, Beyer J, Schoffling K. [The influence of various sulphonylurea derivatives on the oral glucose-tolerance tests in healthy subjects and obese and maturity-onset diabetics (author's transl)]. [German]. *Deutsche Medizinische Wochenschrift* 1974; 99(9):385-388.
- (80) Hoffmann JK. Adjustment of metabolism and eating behaviour of type II diabetics. Results of a six-months treatment with glibenclamide, respectively with acarbose. *Zeitschrift für Allgemeinmedizin* 1992; 68(29):970-977.
- (81) Hoffmann J. Acarbose and glibenclamide in type-II diabetes. A comparative study on efficacy and side effects (therapeutical news). *Münchener Medizinische Wochenschrift* 1990; 132(31-32):487-490.
- (82) Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. *Diabetes Care* 1994; 17(6):561-566.
- (83) Hollander P, Bunkerslawson T, Bergenstal R, Mazze R. A Randomized Clinical Trial of Glyburide Versus Insulin Using Staged Diabetes Management to Achieve Euglycemia in Niddm. *Diabetologia* 1992; 35:A198.
- (84) Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE et al. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. *Diabetes Care* 2001; 24(6):983-988.
- (85) Howes LG. Cardiovascular effects of sulphonylureas: Role of K(ATP) channels. *Diabetes, Obesity and Metabolism* 2000; 2(2):67-73.
- (86) Hristov V, Sheinkova G, Simeonov S, Botushanov N, Valkov Y, Tzinlikov I. Clinical assessment of glimepiride (Amaril) in the treatment of type 2 diabetes mellitus patients (results of a multicenter study). *Endocrinologia* 2002; 7(1):30-35.

- (87) Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. *Journal of Medicinal Food* 2007; 10(3):543-547.
- (88) Inukai K, Watanabe M, Nakashima Y, Sawa T, Takata N, Tanaka M et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. *Diabetes Research and Clinical Practice* 2005; 68(3):250-257.
- (89) Irsigler K, Ogris E, Steinhardt T, Brandle J, Regal H, Zdolsek I. [Comparison of glibenclamide, gliquidone, glisoxepide and placebo in maturity onset diabetics of differing degrees of severity (author's transl)]. [German]. *Wiener Klinische Wochenschrift* 1979; 91(16):541-550.
- (90) Ishizuka T, Taniguchi O, Yamamoto M, Kajita K, Nagashima T, Takeda N et al. Thrombin-induced platelet aggregation, phosphoinositide metabolism and protein phosphorylation in NIDDM patients treated by diet, sulphonylurea or insulin. *Diabetologia* 1994; 37(6):632-638.
- (91) Jackson WP, Vinik AI. Preliminary trial of a powerful new sulphonylurea in maturity-onset diabetes-HB419 (glibenclamide). *South African Medical Journal* 1969; 43(32):1002-1004.
- (92) Jain R, Osei K, Kupfer S, Perez AT, Zhang J. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. *Pharmacotherapy* 2006; 26(10):1388-1395.
- (93) Jerums G, Murray RML, Seeman E. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: A two-year controlled study. *Diabetes Research and Clinical Practice* 1987; 3(2):71-80.
- (94) Jibrán R, Suliman MI, Qureshi F, Ahmed M. Safety and efficacy of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients. *Pakistan Journal of Medical Sciences* 2006; 22(4):385-390.
- (95) Johnston AT, Ireland JT. A comparison of glibenclamide and chlorpropamide in the treatment of non-obese maturity onset diabetics. *Postgraduate Medical Journal* 1970; December(Suppl):98-100.
- (96) Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. *The Journal of Clinical Endocrinology and Metabolism* 1997; 83(5):1515-1522.
- (97) Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. *Diabetic medicine: a journal of the British Diabetic Association* 1990; 7(6):510-514.
- (98) Joshi A, Gupta BS, Sharma SK, Singh V, Chaturvedi MK, Singhal A et al. Comparative study of repaglinide with glibenclamide in the management of type 2 diabetes mellitus [abstract no:12]. *Journal of the Association of Physicians of India* 2002; 50.

- (99) Kakhnovskii IM, Koroleva TV, Zakharchenko VN, Larionov SN. A comparative evaluation of the effect of glurenorm and sulfonylurea preparations on the intravascular microcirculatory indices in type-II diabetes mellitus. *Problemy Endokrinologii* 1993; 39(2):7-9.
- (100) Kaku K, Rasmussen MF, Nishida T, Seino Y. Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs glibenclamide in patients with type 2 diabetes. *J Diabetes Invest* 2011; doi: 10.1111/j.2040-1124.2011.00128.x.
- (101) Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. *Current Medical Research and Opinion* 2010; 26(5):1013-1022.
- (102) Liraglutide is statistically superior to glibenclamide at controlling glycemia and weight, with low hypoglycemic risk, and improves beta-cell function in Japanese Subjects with T2D. *Diabetes*; 2009.
- (103) Zdravkovic M. Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes. [www.clinicaltrials.gov](http://www.clinicaltrials.gov) [ 2006
- (104) Kanda T. Effects of Oral Antidiabetic Agent on Carbohydrate and Lipid Metabolism in Mildly Obese Patients with Diabetes Mellitus: A Randomized Comparative Study of Acarbose and Sulfonylurea. *Rinsho to Kenkyu (The Japanese Journal of Clinical and Experimental Medicine)* 1998; 75(12):2757-2763.
- (105) Kanoun F, Ben Rehaïem B, Mekaouar A, Abdennebi E, Ftouhi B, Idriss S et al. Secondary failure of oral hypoglycaemic agents (OHA) in the treatment of non insulin-dependent diabetic (NIDDM) patients: Effects of carbohydrate and caloric restrictive diet. *Revue Francaise d'Endocrinologie Clinique - Nutrition et Metabolisme* 1996; 37(6):529-536.
- (106) Kovacevic I, Profozic V, Skrabalo Z, Cabrijan T, Zjacic-Rotkvic V, Goldoni V et al. Multicentric clinical trial to assess efficacy and tolerability of acarbose (BAY G 5421) in comparison to glibenclamide and placebo. *Diabetologia Croatica* 1997; 26(2):83-89.
- (107) Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. *Circulation* 2005; 111(19):2525-2531.
- (108) Lecomte MJ, Luyckx AS, Lefebvre PJ. Plasma glucagon and clinical control of maturity-onset type diabetes. Effects of diet, placebo and glipizide. *Diabete et Metabolisme* 1977; 3(4):239-243.
- (109) Levy J, Vandenberg M, Grunberger G. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus. Effects on blood pressure and glucose tolerance. *American Journal of Hypertension* 1995; 8(5 I):445-453.
- (110) Li H, Li W, Gu Y, Han Y, Wang J, Xu B et al. Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-

- secretagogue administration.[Erratum appears in *Diabetes Res Clin Pract.* 2009 Sep;85(3):342]. *Diabetes Research & Clinical Practice* 2009; 84(2):158-162.
- (111) Lim P, Khoo OT. Metformin compared with tolbutamide in the treatment of maturity-onset diabetes mellitus. *The Medical Journal of Australia* 1970; 1(6):271-273.
- (112) Lindbjerg IF, Christoffersen EM, Kuusisto A, Lodahl K, Sagild U, Sterling N et al. Clinical comparison between glibornuride (Glutril) and tolbutamide in maturity-onset diabetes: a controlled double-blind trial. *Current Therapeutic Research, Clinical and Experimental* 1976; 20(3):277-282.
- (113) Liu GC, Coulston AM, Lardinois CK, Hollenbeck CB, Moore JG, Reaven GM. Moderate weight loss and sulfonylurea treatment of non-insulin-dependent diabetes mellitus. Combined effects. *Archives of Internal Medicine* 1985; 145(4):665-669.
- (114) Lomuscio A, Vergani D, Marano L, Castagnone M, Fiorentini C. Effects of glibenclamide on ventricular fibrillation in non-insulin-dependent diabetics with acute myocardial infarction. *Coronary Artery Disease* 1994; 5(9):767-771.
- (115) Madsbad S, Kilhovd B, Lagert I, Mustajoki P, Dejgaard A. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: A 1-year multicentre study. *Diabetic Medicine* 2001; 18(5):395-401.
- (116) Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. *Diabetes Research & Clinical Practice* 2002; 58(1):45-53.
- (117) Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. *Diabetes Research and Clinical Practice* 1999; 43(3):155-166.
- (118) Mazzone T, Meyer PM, Feinsein SB, Davidson MH, Kondos GT, RB et DÃg. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. *JAMA : the journal of the American Medical Association* 2006; 296(21):2572.
- (119) Memisogullari R, Akcay F, Coskun A, Korkmaz U. Comparison of gliclazide treatment with diet therapy on acute phase protein levels in patients with type 2 diabetes. *Turkish Journal of Medical Sciences* 2009; 39(1):73-76.
- (120) Meneilly GS. Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. *Diabetes Technology and Therapeutics* 2011; 13(1):63-65.
- (121) Mogensen EF, Worm J, Mikkelsen BO. Clinical comparison between glibornuride (Glutril) and glibenclamide in maturity-onset diabetes: a controlled double-blind trial. *Current Therapeutic Research, Clinical and Experimental* 1976; 19(6):559-564.
- (122) Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. *Journal of Diabetes and Its Complications* 2000; 14(5):250-254.
- (123) Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type

- 2 diabetic nephropathy patients. *Metabolism: Clinical and Experimental* 2004; 53(10):1382-1386.
- (124) Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. *Diabetes/Metabolism Research and Reviews* 2006; 22(5):385-389.
- (125) Nathan DM, Roussel A, Godine JE. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. *Annals of Internal Medicine* 1988; 108(3):334-340.
- (126) Nikkilä K, Groop L. Glibenclamide and gliquidone in the treatment of non-insulin-dependent diabetes mellitus. *Acta Medica Scandinavica* 1982; 211(1-2):13-17.
- (127) Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *JAMA* 2008; 299(13):1561-1573.
- (128) Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. *Diabète & Métabolisme* 1991; 17(1 Pt 2):209-212.
- (129) Omrani GHR, Lari OB, Mehdizadeh AR, Zare N, Saadat N. Comparison of serum homocysteine level in Metformin versus glibenclamide treated type 2 DM patients. *Iranian Journal of Diabetes and Lipid Disorders* 2005; 4(2):E4+E4i-E4viii.
- (130) Osei K, Rhinesmith S, Gaillard T, Schuster D. Metabolic effects of chronic glipizide gastrointestinal therapeutic system on serum glucose, insulin secretion, insulin sensitivity, and hepatic insulin extraction in glucose-tolerant, first-degree relatives of African American patients with type 2 diabetes: new insights on mechanisms of action. *Metabolism: Clinical and Experimental* 2003; 52(5):565-572.
- (131) Papa G, Fedele V, Rizzo MR, Fioravanti M, Leotta C, Solerte Se. Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. *Diabetes Care* 2006; 29(8):1918-1920.
- (132) Marena S, Pagani A, Montegrosso G, Boella G, Pagano A, De Michieli F et al. Comparison of miglitol and glibenclamide in non insulin-dependent diabetic patients. *Giornale Italiano di Diabetologia* 1993; 13(4):383-388.
- (133) Pagano G, Marena S, Corgiat-Mansin L, Cravero F, Giorda C, Bozza M et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. *Diabète & Métabolisme* 1995; 21(3):162-167.
- (134) Marena S, Pagani A. Miglitol vs glibenclamide in non-insulin dependent diabetes mellitus [abstract]. *European Journal of Clinical Investigation* 1993; 23 Suppl 1:A43.

- (135) Perez A, Spanheimer R, Khan M. Glycaemic Control in Patients With Type 2 Diabetes: the Effects of Pioglitazone Vs Glyburide in a 3-Year Randomized Double-Blind Trial. *Diabetologia* 2006; 49:0807.
- (136) Perriello G, Pampanelli S, Di Pietro C, Brunetti P, Italian Pioglitazone S. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. *Diabetic Medicine* 2006; 23(3):246-252.
- (137) Perriello G, Pampanelli S, Brunetti P, Di Pietro C, Mariz S, Italian Pioglitazone S. Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes. *Diabetes & Vascular Disease Research* 2007; 4(3):226-230.
- (138) Quatraro A, Consoli G, Magno M, Caretta F, Nardoza A, Ceriello A et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? *Annals of Internal Medicine* 1990; 112(9):678-681.
- (139) Rao VU, Alokzai D, Voloshko P, Schiller NB. Effect of the dual peroxisome proliferator-activated receptor alpha/gamma agonist, muraglitazar, on cardiac structure and function in type 2 diabetic patients. *Journal of the American College of Cardiology* 2010; Conference: American College of Cardiology's 59th Annual Scientific Session and i2 Summit: Innovation in Intervention Atlanta, GA United States.
- (140) Center for Drug Evaluation and Research. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2000/020741\\_S009\\_PRANDIN\\_TABS\\_AP.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020741_S009_PRANDIN_TABS_AP.pdf) [ 2000
- (141) Novo Nordisk. Unpublished data for trial: AGEE/DCD/047/B/F/I. 1997. Ref Type: Unpublished Work
- (142) Novo Nordisk. Unpublished data for trial: AGEE/DCD/046/UK. 1997. Ref Type: Unpublished Work
- (143) Rosenstock J, Corrao PJ, Goldberg RB, Kilo C. Diabetes control in the elderly: a randomized, comparative study of glyburide versus glipizide in non-insulin-dependent diabetes mellitus. *Clinical Therapeutics* 1993; 15(6):1031-1040.
- (144) Mauersberger H, Rosenthal JH. -Wirkung von endogenem Insulin sowie Acarbose oder Glibenclamide in der Therapie der Hypertonie bei Typ-2 Diabetikern. *CF-Journal* 2001; 1:26-28.
- (145) Rosenthal J, Mauersberger H. Hypertension in type 2 diabetic patients- effects of endogenous insulin and antidiabetic therapies. *The American Journal of Hypertension* 2000; 13(4 Suppl 1):S81.
- (146) Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. *Clinical Drug Investigation* 2002; 22(10):701.
- (147) Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanfeld M et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination



- therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 2009; 373(9681):2125-2135.
- (148) Rupprecht E, König E, Limmer J. Clinical evaluation of gliquidone-short acting sulfonylurea derivative-comparison with glibenclamide and gliclazide. *Polski Tygodnik Lekarski* 1993; 48(Suppl 1):31-32.
- (149) Saadatnia M, Siavash M, Amini A, Hamid A. Cognitive impairment in type 2 diabetic patients using metformin or sulfonylurea: A comparative study. Conference: Alzheimer's Association International Conference on Alzheimer's Disease Vienna Austria 2009.
- (150) Salman S, Salman F, Satman I, Yilmaz Y, Özer E, Sengül A et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. *Current Medical Research and Opinion* 2001; 16(4):296-306.
- (151) Sami T, Kabadi UM, Moshiri S. The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents. *The Journal of Family Practice* 1996; 43(4):370-374.
- (152) Sasahara T, Jerums G, Nestel P. Effects of insulin therapy and glycemic control on distribution of HDL alpha and pre-beta subfractions in non insulin-dependent diabetic subjects. *Nutrition, Metabolism, and Cardiovascular Diseases* 1999; 9(1):19-24.
- (153) Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. *European Journal of Clinical Investigation* 2004; 34(8):535-542.
- (154) Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein Pe. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. *International Journal of Clinical Practice* 2010; 64(5):562-576.
- (155) Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. *Diabetes Care* 1997; 20(5):687-691.
- (156) Shihara N, Kitaoka M, Inagaki N, Kadowaki T, Koumoto S, Satoh J et al. Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study. *Journal of Diabetes Investigation* 2011; doi: 10.1111/j.2040-1124.2011.00115.x.
- (157) Shihara N. A Comparative Study of Insulin Secretagogue (SU Agent) and Insulin sensitizers (TZD). 2010. <http://apps.who.int/trialsearch/trial.aspx?trialid=JPRN-UMIN000004582>
- (158) Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy-restriction. *Journal of Diabetes*; 2009.

- (159) Speiser P, Schernthaner G. Sulfonylurea omission leads to a significant deterioration of metabolic state in diabetes mellitus type II: A placebo-controlled double-blind study. *Klinische Wochenschrift* 1989; 67(Suppl 16):204.
- (160) Fölsch UR, Spengler M, Boehme K, Sommerauer B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated type 2 diabetic subjects: two long-term comparative studies. *Diabetes, Nutrition and Metabolism* 1990; 3(Suppl. 1):63-68.
- (161) Spengler M, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM). *Hormone and Metabolic Research Supplement Series* 1992; 26(Suppl. 26):50-51.
- (162) Spengler M, Hänsel G, Boehme K. 6 months monotherapy of NIDDM with acarbose or glibenclamide. In: Lefébrevre PJ, Standl E, editor(s) *New Aspects in Diabetes Treatment strategies with Alpha-Glucosidase Inhibitors Third International Symposium on Acarbose Berlin-New York: Walter de Gryter* 1992;243-246.
- (163) Spengler M, Hänsel M, Boehme K. Acarbose and glibenclamide in type II diabetes. *Zeitschrift für Allgemeinmedizin* 1990; 65(22):606-610.
- (164) Spengler N, Hänsel G, Boehme K. Efficacy of 6 months monotherapy with glucosidase inhibitor acarbose versus sulphonylurea glibenclamid on metabolic control of dietary treated type II diabetics. *European Journal of Clinical Investigation* 1989; 19 (2 Pt II):A71.
- (165) Sung BH, Izzo JL J, Dandona P, Wilson MF. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. *Hypertension* 1999; 34(1):83-88.
- (166) Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI et al. Rosiglitazone reduces urinary albumin excretion. *Journal of Human Hypertension* 2003; 17(1):7-12.
- (167) St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. *Diabetes Care* 2002; 25(11):2058-2064.
- (168) Tan M, Johns D, González G, Antón O, Fabián G, Flores-Lozano F et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. *Clinical Therapeutics* 2004; 26(5):680-693.
- (169) Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. *Diabetic Medicine: a journal of the British Diabetic Association* 2004; 21(8):859-866.

- (170) Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. *Diabetes Care* 2005; 28(3):544-550.
- (171) Teramoto T, Yamada N, Shirai K, Saito Y. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. *Journal of Atherosclerosis and Thrombosis* 2007; 14(2):86-93.
- (172) Liraglutide, a human GLP-1 analogue, offers sustained and greater reduction in HbA1c, fasting plasma glucose and weight compared with glimepiride over 2 years, with lower hypoglycaemic risk, in patients with Type 2 diabetes: LEAD-3 extension study. *Diabetic Medicine*; 2009.
- (173) Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism* 2011; 13(4):348-356.
- (174) Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet* 2009; 373(9662):473-481.
- (175) Garber AJ, Henry R, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a human GLP-1 analogue, maintains greater reductions in HbA1c, FPG and weight than glimepiride over 2 years in patients with type 2 diabetes: LEAD-3 extension study. *Diabetologia* 2009; Conference: 45th EASD Annual Meeting of the European Association for the Study of Diabetes Vienna Austria.
- (176) Hale P. To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c (LEAD-3). *ClinicalTrials.gov* [ 2006
- (177) Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L et al. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism* 2010; 12(7):604-612.
- (178) Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. *Drug Safety* 2009; 32(9):787-800.
- (179) Tovi J, Svanborg E, Nilsson BY, Engfeldt P. Diabetic neuropathy in elderly Type 2 diabetic patients: effects of insulin treatment. *Acta Neurologica Scandinavica* 1998; 98(5):346-353.
- (180) Toyota T, Fukao A, Kaneko T, Suda T, Maruhama Y, Sato J. [Clinical Evaluation of Glimepiride (HOE490) in Non-Insulin-Dependent Diabetes Mellitus: A Double-Blind Placebo-Controlled Study/Phase III Additional Study]. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)* 1997; 13(17):4457-4478.

- (181) Tsumura K. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. *Diabetes Research and Clinical Practice* 1995; 28 Suppl:147-149.
- (182) Umpierrez GE, Clark WS, Steen MT. Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. *Diabetes Care* 1997; 20(4):479-483.
- (183) The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline results. *Diabetes* 1970; 19(2):747-783.
- (184) The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. *Diabetes* 1976; 25:1129-1153.
- (185) The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. *Diabetes* 1970; 19(suppl 3):789-830.
- (186) Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). *Diabetologia* 2005; 48(5):868-877.
- (187) Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. *Diabetic Medicine* 1998; 15(4):297-303.
- (188) Mehta Z, Cull C, Stratton I, Yudkin J, Jenkinson C, Fletcher A et al. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). *Diabetes Care* 1999; 22(7):1125-1136.
- (189) UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352(9131):837-853.
- (190) Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, UK Prospective Diabetes S. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). *Diabetes Care* 2002; 25(2):330-336.
- (191) Van de Laar FA, Lucassen PLBJ, Kemp J, Van de Lisdonk EH, Van Weel C, Rutten GEHM. Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice?: A randomised controlled trial. *Diabetes Research and Clinical Practice* 2004; 63(1):57-65.
- (192) Vray M, Attali JR. Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. *Diabete et Metabolisme* 1995; 21(6):433-439.

- (193) Wang WL, Zhang BZ, Zhang SL, Xu DF, Wei XH. Multicenter randomized controlled trial of domestic gliclazide and tolbutamide in the treatment of non-insulin-dependent diabetes mellitus. *Chinese Journal of Pharmacoepidemiology* 1994; 3(3):119-121.
- (194) Watanabe I, Tani S, Anazawa T, Kushihiro T, Kanmatsuse K. Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. *Diabetes Research and Clinical Practice* 2005; 68(2):104-110.
- (195) Wolffenbittel BH, Weber RF, van Koetsveld PM, Weeks L, Verschoor L. A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy. *Diabetic Medicine* 1989; 6(6):520-525.
- (196) Wolffenbittel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. *Diabetes Care* 1999; 22(3):463-467.
- (197) Wu CZ, Pei D, Hsieh AT, Wang K, Lin JD, Lee LH et al. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. *Archives of Pharmacal Research* 2010; 33(3):411-416.
- (198) Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. *Diabetes Research and Clinical Practice* 2009; 83(1):54-60.
- (199) Zhang YN, Cui C, Chang ML, Wu W, Yu WG, Liu FC et al. Interventional effects of rosiglitazone in type 2 diabetes elderly male patients combined with atherosclerosis. *Chinese Journal of Clinical Rehabilitation* 2005; 9(39):58-61.
- (200) Zhou, W. [60 cases of type II diabetes mellitus treated by Zishen Jiangtang Decoction compared with 25 cases treated by Glibenclamide in the control group]. *Journal Title: Zhejiang Journal of Traditional Chinese Medicine [Zhe Jiang Zhong Yi Za Zhi]* 1999;(8):328.